Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
THE WOODLANDS, Texas, Nov. 10, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2011. Financial...
-
THE WOODLANDS, Texas, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced data from its recently completed ZA-204 study demonstrated that the 25 mg dose of...
-
THE WOODLANDS, Texas, Sept. 20, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has commenced the dosing of the final cohort in its Phase 2 low-dose trial of...
-
THE WOODLANDS, Texas, Sept. 12, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it believes that enough patients have enrolled in each of its three ongoing...
-
Company receives guidance from FDA in pre-IND teleconference for IND requirements No additional preclinical studies are required THE WOODLANDS, Texas, Sept. 8, 2011 (GLOBE NEWSWIRE) -- Repros...
-
THE WOODLANDS, Texas, Sept. 7, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported results from the lowest three doses of its ongoing Phase II study of oral Proellex...
-
THE WOODLANDS, Texas, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)today announced it will present an update on its Androxal® and Proellex® clinical programs...
-
THE WOODLANDS, Texas, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2011. Financial Results...
-
THE WOODLANDS, Texas, Aug. 3, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided unaudited top line results for an interim analysis it has performed on its Phase 2...
-
THE WOODLANDS, Texas, June 23, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has commenced enrolling subjects in the 9 mg cohort in the Company's low dose...